#USA #New York #Gross Law Firm #Applied Therapeutics #APLT

Attention Shareholders of Applied Therapeutics, Inc.

In a significant development for shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT), The Gross Law Firm is reaching out with a crucial notice aimed at those who purchased shares during the specified period. If you have invested in APLT between January 3, 2024, and December 2, 2024, your rights as a shareholder may be impacted, and it's important to understand the steps you can take.

Background of the Issue

On November 27, 2024, Applied Therapeutics made headlines by announcing that it received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for govorestat, a drug that was anticipated as a key candidate for the company. The CRL indicated deficiencies in the clinical application, which substantially affected the company's market performance.

The immediate fallout from this announcement led to a dramatic decline in APLT's share price. From a closing price of $10.21 on November 26, the stock plummeted to $8.57 the following day, continuing to fall to $2.03 by November 29 and reaching a low of $1.75 on December 2, representing a staggering decrease of over 80%.

Recent Developments

Adding salt to the wound, on the evening of December 2, 2024, Applied Therapeutics disclosed that it had received a